High call volumes

Our member and provider services may be experiencing higher than normal call volumes from 12/22/25-1/9/26 due to a large number of staff being out of office.  We encourage you to utilize alternative forms of communication including secured messaging through online Member Services and Availity Essentials Provider Portal.

Show More

BCBSND district offices will be closed to the public on Friday, Dec. 26.

This includes Bismarck, Grand Forks, Jamestown and Minot. Need help? We’re here for you! Log in at BCBSND.me or call 844-363-8457.

Show More

We are unable to accept walk-ins on Friday, Dec. 26, and Friday, Jan. 2., due to short staffing.


Show More

Long-Acting Insulin Prior Authorization Program Update

Impacting Commercial Lines of Business

Effective Aug. 1, 2025, Blue Cross Blue Shield of North Dakota (BCBSND) has updated the Long-Acting Insulin Prior Authorization (PA) Program to include additional agents: Toujeo, Basaglar and Insulin glargine 300 units/ml. 

The complete list of program target agents is shown below.

Preferred Agent(s)

  • Glargin-yfgn (insulin glargine-yfgn)
  • Semglee (insulin glargine-yfgn)
  • Toujeo (insulin glargine)

Non-Preferred Target Agent(s)

  • Insulin glargine
  • Lantus (insulin glargine)
  • Rezvoglar (insulin glargine-aglr)
  • Basaglar (insulin glargine)
  • Insulin glargine 300 units/ml

To view this PA program summary, visit Long Acting Insulin Prior Authorization with Quantity Limit Program Summary.

Questions?
Contact our Provider Service Center at 800-368-2312.